| __timestamp | Amphastar Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 11606000000 |
| Thursday, January 1, 2015 | 46974000 | 10313000000 |
| Friday, January 1, 2016 | 47298000 | 9762000000 |
| Sunday, January 1, 2017 | 50918000 | 9830000000 |
| Monday, January 1, 2018 | 58044000 | 10102000000 |
| Tuesday, January 1, 2019 | 63109000 | 10615000000 |
| Wednesday, January 1, 2020 | 65157000 | 8955000000 |
| Friday, January 1, 2021 | 68920000 | 9634000000 |
| Saturday, January 1, 2022 | 66592000 | 10042000000 |
| Sunday, January 1, 2023 | 80393000 | 10504000000 |
In pursuit of knowledge
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses.
From 2014 to 2023, Merck's SG&A expenses have fluctuated, peaking in 2014 and 2019, with a notable dip in 2020. This reflects a strategic shift, possibly due to market conditions or internal restructuring. In contrast, Amphastar has steadily increased its SG&A expenses by approximately 99% over the same period, indicating a focus on expansion and market penetration.
These trends highlight the different strategies employed by large and mid-sized pharmaceutical companies in navigating the competitive landscape. As the industry evolves, understanding these financial dynamics becomes essential for investors and stakeholders.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Lantheus Holdings, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE